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Data analysisa b s t r a c t
Medication exposure is an important variable in virtually all clinical research, yet there is great variation
in how the data are collected, coded, and analyzed. Coding and classiﬁcation systems for medication data
are heterogeneous in structure, and there is little guidance for implementing them, especially in large
research networks and multi-site trials. Current practices for handling medication data in clinical trials
have emerged from the requirements and limitations of paper-based data collection, but there are
now many electronic tools to enable the collection and analysis of medication data. This paper reviews
approaches to coding medication data in multi-site research contexts, and proposes a framework for
the classiﬁcation, reporting, and analysis of medication data. The framework can be used to develop tools
for classifying medications in coded data sets to support context appropriate, explicit, and reproducible
data analyses by researchers and secondary users in virtually all clinical research domains.
 2014 Elsevier Inc. All rights reserved.1. Introduction
Standardized coding and classiﬁcation of medication data en-
able comparability within and across research studies and can
bridge clinical and research networks and applications. However,
there is currently no explicit standards-based process for organiz-
ing granular medication codes (e.g., ‘‘acetaminophen’’, ‘‘Tylenol’’, or
‘‘acetaminophen 325 mg oral tablet’’) into classes deﬁned by various
drug properties (e.g., ‘‘antipyretic’’ or ‘‘prostaglandin receptor antag-
onists’’). Such a process is badly needed to ensure efﬁcient, repro-
ducible classiﬁcation and analysis.
While property-based drug classiﬁcation seems straightfor-
ward, there is ambiguity in the deﬁnitions of classes in coded data
sets (e.g., ‘‘Does the class ‘antibiotics’ in this analysis include topical
antibiotics?’’), new indications (‘‘Is Donnatol™ included as a seizure
medication in this analysis?’’), and new products (‘‘Is the recently ap-
proved drug Ravicti™ included in the group of urea cycle disorder
medications in this data set?’’). Comprehensive reference terminol-
ogy valid across the spectrum of clinical domains can ensure that
the class memberships used in categorical analyses are explicit
and easily reproducible, enabling comparability of different data
sets. In this paper, we examine current approaches, propose a
framework for standard medication coding and classiﬁcation sys-
tems, and identify needed research and tools.2. Background
2.1. Medication coding systems
Current systems for coding medication data include granular
medication entities (e.g., the Unique Ingredient Identiﬁers [UNII]
for active ingredients and chemical substances, and the National
Drug Codes [NDC] for packaged products maintained by the U.S.
FDA) with varying levels of adherence to sound coding manage-
ment principles [1–3]. Other U.S. coding systems include the NDC
Directory [4] and RxNorm [5,6], both of which include route of
administration, in addition to the information on active ingredi-
ents, trade and generic names, drug strength, dosage form, and
package size information found in the NDC codes. RxNorm has
been shown to have near perfect coverage of ambulatory e-pre-
scriptions [7] and it is being increasingly used in a variety of appli-
cations [8]. RxNorm does not include codes for dietary
supplements such as mineral and herbal preparations, although
there is no designated standard in this area for all research studies
[9]. (It should be noted that the WHO Herbal Dictionary is used in
many industry-sponsored trials [10].) In general, less speciﬁcity is
required for coding of medications for research than is for clinical
purposes (which require identiﬁers for branded products to sup-
port prescribing and pharmacy management activities).
2.2. Medication classiﬁcation systems
RxNorm is linked to source vocabularies in the National Library
of Medicine’s (NLM) Uniﬁed Medical Language System (UMLS),
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NDF-RT was created by the Department of Veterans Affairs (VA) to
organize drugs in the VA formulary, and it uses a logic-based model
to group drug products into classes based on chemical structure,
mechanism of action, physiological effect, drug–disease relation-
ship describing therapeutic intent, pharmacokinetics describing
the mechanisms of absorption and distribution of an administered
drug in a body (e.g., hepatic metabolism), and legacy VA-NDF clas-
ses for pharmaceutical preparations (e.g., non-opioid analgesic).
NDF-RT is the standard for the U.S. FDA’s Structured Product Label
(SPL) initiative [11].
Other reference terminologies and classiﬁcations that have for-
mal systems for organizing and classifying medications include the
Anatomical Therapeutic Chemical (ATC) Classiﬁcation System
maintained by the WHO Collaborating Centre for Drug Statistics
Methodology and used widely in Europe [12]. Proprietary medica-
tion systems obviously use a formal class organization, presumably
based on the American Hospital Formulary Service (AHFS Drug
Information) [13,14], but they are not available for research or
comparison. The fairly new Chebi ontology of chemical compounds
of biological interest also contains medication compounds and
information related to their molecular and biological function
and interactions [15–17]. Existing reference terminologies and
classiﬁcations, however, support different uses and user groups,
and the identiﬁcation of the most appropriate classiﬁcation system
is driven by the research question and the business case.
2.3. Current medication coding and classiﬁcation in clinical research
To date, paper workﬂows have dominated clinical research [18].
Medication data for clinical trials are typically collected as free text
and coded later, usually by a medical coder employed by the trial
sponsor; errors and uncertainties are coded after data collection
as they are discovered [19]. The completeness of data collection de-
pends in part on the method of elicitation used by the investigator
(e.g., open ended questions, symptom checklists) [19]. In industry-
sponsored trials, quality control checks are performed by a clinician
or pharmacist; reported medications are often compared with re-
ported events/diseases to verify the accuracy of the information.
There has been little empirical research on the quality of coding
in clinical trials. A 2012 systematic review [19] found only one
published study on the validity and inter-rater reliability of ad-
verse event coding using Medical Dictionary for Regulatory Activ-
ities (MedDRA) [20]. That study found that 12% of sampled
adverse events were coded differently by two coders, and 8% of
the coding was declared medically inaccurate by experts. Similarly,
White et al. looked at 204 post marketing surveillance events to
examine the impact of different classiﬁcation systems on the iden-
tiﬁcation of adverse events [21]. When the same verbatim text was
coded with terms from MedDRA and the WHO Adverse Reaction
Terminology (WHO-ART), 32 coded pairs (16%) of events were
rated as medically different by expert reviewers.
Richesson et al. found high completion rates using RxNorm for
coding in two different multi-site studies, but they did not evaluate
coding accuracy [22]. The designation of the WHO Drug Dictionary
as a medication coding standard for regulated clinical trials may
eliminate the need for comparative research on coding schemes
in industry-sponsored trials, but observational studies do not have
the same restrictions. As electronic health records (EHRs) become
more widely adopted, there will be greater potential to capture
medication data from clinical repositories; the Clinical Data Stan-
dards Interchange Consortium (CDISC) is driving these efforts as
part of its Electronic Source Data Interchange (eSDI) Group [18].
The emergence of ‘‘big data’’ and increasing interest in observa-
tional research are creating a sizable constituency of prospective
data users who will demand free and open data standards. Thuscomparative studies of the ﬁtness of various medication classiﬁca-
tions, and ways to integrate them into various workﬂows, are ur-
gently needed.
‘‘Big data’’ necessitate specialized data centers with massive
capacities for data collection, storage, exchange, aggregation, visu-
alization, and analysis [23]. Data centers for research networks and
multi-site trials can beneﬁt greatly from the use of standards to
support data collection and analysis [24], yet there is little pub-
lished guidance on how to implement these in large research net-
works and multi-site trials. The framework we provide can guide
the development of tools to support improvements and standard-
ization of medication data and enable sharing of research data sets
and meaningful interpretation, comparison, communication, and
application of results.
3. Framework for handling medication data in research
environments
The major issues related to the standardization of medication
data are (1) selection of a standardized medication coding scheme;
(2) development of a process for collecting and coding data, includ-
ing systems and interfaces to support data collection, entry, or cod-
ing that are customized to study needs and workﬂows; (3) choice
of a classiﬁcation system to support reporting and analysis; and
(4) development of methods and tools for inserting the classiﬁca-
tion into the data management and analysis workﬂow. Fig. 1 rep-
resents this framework, including where potential sources of
error lie and points of opportunity for informatics tools and theo-
ries to reduce error and increase efﬁciency.
3.1. Selection of a standard coding system
Medication data must be coded for analysis, and data centers
can beneﬁt from the re-use of tools, personnel, and training mate-
rials by using the same medication system for all studies. Cimino’s
desiderata [2] has obvious relevance for selecting a structurally
sound coding system, but other considerations (e.g., regulatory
reporting requirements, sponsor requirements, costs, licensing is-
sues, and assurance of ongoing maintenance) are often more criti-
cal to research networks.
In the U.S., RxNorm is the designated standard for representing
medication brand names, clinical drug names, and allergies/adverse
events formedication products [25]. RxNormuses a relationalmod-
el to name drugs at different levels of speciﬁcity, ranging from ac-
tive ingredients to packaged products with trade name, dosage,
formulary and packing information. This is an appealing feature
for data centers supporting multiple studies with multiple sources
of medication data. RxNorm includes content from the FDA (UNII
and NDC codes) as well as codes from commercial medication
knowledge vendors. Because a core objective of the U.S. Meaningful
Use regulations is to increase the use of computer provider order
entry [26], it is likely that future regulations will require providers
to use RxNorm for primary medication order entry [8].
Several organizations have reported mapping local medication
code lists and free text data to RxNorm [7,27–30]. Mapping
approaches include syntactic, semantic, and hybrid methods [31].
Others have demonstrated the feasibility of using RxNorm as a
primary coding source (for medical history) [31] and research
[9,32–34]. Bennett has described a live clinical system implement-
ing RxNorm for primary data capture [31].
3.2. Systems and processes for implementing a medication coding
system
As shown in Fig. 1, medication coding systems can be applied
before, at, or after (electronic or paper-based) data collection. Once
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and procedures must be developed. Generally, coding tools can be
integrated into user interfaces by allowing users to either select a
code from a pre-conﬁgured drop list or from a search or browsing
interface [31]. Desired features of clinical terminology servers for
distributed coding are well summarized in Dr. Chute’s desiderata
[35]; they include word normalization, word completion, target
terminology speciﬁcation, spelling correction, lexical matching,
term completion, semantic locality, term composition and decom-
position. The Rare Diseases Clinical Research Network (RDCRN)
uses embedded RxNorm search features in the online data collec-
tion forms for all studies [36]. Selection of RxNorm codes are done
by distributed research staff, on the assumption that researchers
are best suited to check ambiguous or uncertain entries [37].
Resources and logistical issues can limit ability for distributed
coding in some cases, e.g., studies collecting data using postal mail
or whose research staff vary enough between sites that coding con-
sistency is a concern. In multi-national studies, multiple languages
might necessitate a centralized approach to coding. For example,
The Environmental Determinants of Diabetes in the Young (TED-
DY) study, which collects reported pediatric medication use from
four European countries, uses a pre-conﬁgured approach, and has
developed an online code-book containing country-speciﬁc trade
names mapped to corresponding generic drug names and RxNorm
codes [38].
3.3. Selection of a classiﬁcation system to support reporting and
analysis
The requirements of a data center and study sponsors, as well as
empirical and comparative informatics research, should drive theFig. 1. Collection, coding, storage, retrieval, and classiﬁcation of medication data in res
collection, (b) at data entry (electronic or paper), or (c) after collection. Medication clas
analysis preparation and reporting.selection of a medication classiﬁcation system to support data re-
trieval and analysis. There are few published comparisons between
reference terminologies (a term used loosely here to include clas-
siﬁcations and ontologies), but there do appear to be differences.
Mortensen and Bodenreider, for example, identiﬁed discrepancies
between NDF-RT and SNOMED CT medication classes, noting that
there were 390 and 527 classes, respectively, and within the two,
the majority (75.6%) of the VA classes had less than 50% overlap
in medications with the corresponding SNOMED CT classes [39].
These authors suggest that medication entities are more easily
standardized than semantic properties, and advocate that data
should be coded at the medication (rather than class) level and la-
ter classiﬁed at the time of analysis [39].
Recently, Walcer, Gilder, and Jainhey compared the structure
and usability of several pharmacologic classiﬁcations and ontolo-
gies by examining intentional deﬁnitions for ﬁve medication prod-
ucts [40]. They identiﬁed inconsistencies in the organization and
structure of SNOMED CT, NCI Thesaurus, and ATC, although they
found the ATC structure to be more ‘‘user-friendly’’. Using the
metrics of structure, depth, medication coverage, and speciﬁcity,
the authors concluded that the NDF-RT, which classiﬁes medica-
tions by physiologic effects, mechanism of action, established
pharmacologic class, and chemical/ingredients, offers the best
overall classiﬁcation scheme. Others have reported expert (physi-
cian) agreement with the structure and properties of the physio-
logical effects axis for classifying organ speciﬁc and generalized
systemic effects of a random selection of commonly prescribed
medications [41]. Richesson and Pathak found NDF-RT class names
and properties to be comprehensive and adequate for pediatric
medications in the TEDDY study data [42]. They also noted that in-
stances of underspeciﬁed medications (e.g., ‘‘unknown steroid’’,earch studies. Medication coding systems can be applied (a) before research data
siﬁcation systems can be applied (d) at the time of data retrieval or (e) as part of
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coded in medication classiﬁcation systems.3.4. Embedding the classiﬁcation system into analysis workﬂow
Data centers provide leadership and technical support in the
collection, storage, management and distribution of data for anal-
ysis [24]. Consequently, they are well suited to embed standard
classiﬁcation systems into data cleaning and analysis tools and
workﬂows. Pre-analysis tasks include transforming (‘‘re-coding’’)
raw data into variables and categories for computational analysis.
We are not aware of any published workﬂow analyses or studies,
but our experience suggests that researchers classify medication
data in an ad hoc manner, focusing on the classes most relevant
to their analysis, using their ‘‘expert knowledge’’ and information
resources to assign reported medications to appropriate classes,
and later identifying apposite classes for any unassigned
medications.
This lack of a uniform approach to classifying medications in
research data sets is likely to cause duplication of efforts within re-
search networks or data centers, and raise questions about the
reproducibility of analyses and the comparability of medication
classiﬁcations of data sets generated by different research net-
works [44]. Because medication classiﬁcation is done ad hoc, the
association of medications with analysis-appropriate classes is
time-consuming, susceptible to error or variation, and not easily
reportable or reproducible without access to the analysis-speciﬁc
programming code.4. Typology of analysis tasks related to medication data
As shown in Fig. 1, a medication classiﬁcation system can
support tasks related to data retrieval or analysis and reporting
of data by providing property-based classes (e.g., anti-pyretic,
beta-blockers) relevant to a particular research question. OurTable 1




Analytic goal Hypothesis testing
Overall goal To answer research questions
Types of study designs Clinical trials, comparative effectivene
observational designs
Classes determined Before data collection
Content (classiﬁcation) requirements
Property-based Classes determined by Medication properties pre-speciﬁed in
questions
Content Inclusive of research phenomena unde
observation
Breadth of coverage Enough classes to cover medication pr
to pre-speciﬁed research questions
Speciﬁcity of classes (‘‘Depth of coverage’’)
determined by
Research question
Multi-axial classiﬁcation Not essential
Ideal software requirements
Linkage from classiﬁcation system to
medication coding system
Yes
Time of medication classiﬁcation At or after data collection
Type of variable that classiﬁcation will be
used to code
Dichotomous
Type of question each medication entity ‘‘Is <MEDICATION> a <PROPERTY CLAS
Support ‘‘roll-up’’ of data records by
aggregating data into parent classes
Not essentialexperience in data centers leads us to believe that the research
questions requiring medication classiﬁcation represent two differ-
ent use cases and cognitive approaches: deductive reasoning (as
typically applied to hypothesis-driven investigations) and inductive
reasoning (which is relevant to discovery activities, fueled by the
growing availability of clinical and research data for secondary
analyses). Deductive reasoning begins with a general statement,
hypothesis, or theory, and examines the possibilities for reaching
a speciﬁc conclusion. Typical drug efﬁcacy research questions
(e.g., ‘‘Does x inﬂuence the outcome of y?’’) fall under this model,
and medication data are often included in analyses as independent
variables or as potential confounders. Inductive reasoning, in con-
trast, strives to identify broad generalizations from speciﬁc obser-
vations, and is used to generate new hypotheses and theories.
Table 1 contrasts the different features, classiﬁcation needs, and
system design requirements for deductive and inductive ap-
proaches for exploring medication data.
These different reasoning approaches leverage classiﬁcation
systems differently for processing data. In deductive reasoning,
the classes of interest are pre-speciﬁed and represent properties
suspected or known by the investigator to be relevant to the inter-
vention being tested, e.g., ace inhibitors, antifungals, or stimulants.
The classiﬁcation task, therefore, is to determine class membership
(e.g., ‘‘Is <coded drug A> a <beta blocker>?’’ – yes or no) as a dichot-
omous variable for one or more pre-speciﬁed classes for each re-
ported medication.
In contrast, exploratory analysis or data mining activities use an
inductive approach to analysis. The relevant drug properties and
classes are not known at the time of data collection or coding,
but rather are selected based upon the values and frequencies in
the data. In qualitative research, large data sets also are condensed
into smaller analyzable units using categories and concepts that
are derived from the data [43]. Thus, the process of inductive
research is by deﬁnition data-driven, and the medication catego-
ries are generated after examining the collected data. Often the
goal is to ‘‘characterize a data set’’ by classifying medicationInductive
Hypothesis generation
To characterize data sets; data exploration
ss research, some Observational research, data mining and knowledge
discovery, epidemiology (some)
After data collection
research Medication entities present in data set
r control or Inclusive of records in sample data set
operties relevant Enough to classes to represent all medication entities in the
data set





S NAME>?’’ ‘‘What properties does <MEDICATION> have?’’; ‘‘To what
<CLASSES> does <MEDICATION> belong?’’
Essential
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and areas for further exploration. In exploratory analyses related to
the TEDDY study, for example, investigators wanted to visualize
the thousands of instances of 284 generic medications in the data
set; they identiﬁed approximately 20 clinical classes they thought
important and comprehensive, but the data set still included many
medications outside of the 20 classes identiﬁed [44].
In contrast, the classiﬁcation tasks for inductive reasoning
(exploratory research) are related to organizing and visualizing a
data set or large corpus of reported medications. For example, gi-
ven a set of 150 different purported medications, the question is
‘‘what kinds of medications are in this data set? The distribution
of medications in the data set will drive the number of classes to
avoid ‘‘heaping’’ the data (putting too much data into the same cat-
egory) and to ensure that the classiﬁed medication variables show
variance. Using the medications from a given data set, iterative
queries of the reference terminology will identify relevant parent
classes and properties; the distribution of values in the data will
impact group size for each class, which will ultimately to inform
the optimal number and level of speciﬁcity of medication classes
needed to characterize a particular data set. This is similar to the
data-driven extraction of ontologies described by Brewseter et al.
[45], who propose several methods to evaluate the congruence of
an ontology with a given corpus (or data set) for the representation
of knowledge in that given domain. By extension, data-driven que-
ries and evaluations of class-membership medication reference
terminology in a given domain (e.g., pediatrics, oncology) can pro-
duce measures of its ‘ﬁtness’ and identify areas where the ontology
should grow [44].
In both deductive and inductive reasoning, classes relevant to
the analysis task must be selected and then medications classiﬁed
(and re-coded) so that the data set represents reported medica-
tions by class groupings rather than as medication entities. Group-
ings might be dichotomous or categorical, and the group size
requirements of the analytic method determine the number of
classes. This number can be increased by identifying increasingly
speciﬁc subclasses, or by choosing new classes representing differ-
ent properties. The selection of a ﬁnite and meaningful set of med-
ication classes for analysis, however, is complicated by the fact that
drugs have many properties (chemical, mechanistic, and clinical). A
standard robust and multi-axial classiﬁcation can support both
types of reasoning by allowing medications to be classiﬁed by var-
ious properties, at varying levels of speciﬁcity.
Best practices for data management dictate that the categories
of a coded variable in an analysis data set should be both mutually
exclusive (i.e., each medication instance should be assigned to only
one drug class) and exhaustive (i.e., a unique code number should
have been created for each category). The latter requirement often
leads to a residual ‘‘Other’’ category to classify data instances that
are not typical or anticipated. (While ‘‘other’’ and ‘‘not elsewhere
classiﬁed’’ are discouraged in coding systems, they are very useful
and common in data reporting and analysis.).5. Discussion
In an era of transparent research and pressure for data sharing,
there is a great need for standardized methods that can be easily
replicated. Major questions include how to ensure consistent and
accurate medication coding across sites, and how to develop mod-
els and tools for applying classiﬁcation systems (e.g., ontologies,
reference terminologies) to medication data collected in different
studies. Informatics methods that enable researchers to use exist-
ing data sets for new analyses or to replicate previously reported
ﬁndings are badly needed. While many tools exist for collecting,
classifying, and analyzing medication data, the reliability andvalidity of these approaches have not been evaluated. There is no
consensus on research data center requirements and approaches,
although the AMIA CRI summit has become an early forum for such
discussions [46].
While the integration of standard medication classiﬁcations
into query and data analysis systems (e.g., i2b2, JMP, SAS) would
be ideal, current publicly available tools from the NLM offer an
immediate approach to implementing standards that is scalable
yet customizable and adaptive to change. Researchers and data
analysts can use application programming interfaces (API’s),
including the RxMix tool, which leverages UMLS mappings be-
tween RxNorm and NDF-RT medications (at level of ingredients
and clinical drugs), to support a variety of classiﬁcation tasks. Cur-
rent tools allow batch queries for the retrieval of all NDF-RT classes
relevant to a set of RxNorm medication codes, as well as all med-
ication entities in one or more speciﬁed classes. These membership
assignment ﬁles can be distributed to analysts in two-dimensional
spreadsheets as part of a data dictionary, and incorporated into
data cleaning and analysis programs, as SAS macros, for example.
The reference terminology provides an externally maintained stan-
dard, and the data center can develop generic tools and simple
instructions for querying the NDF-RT for speciﬁc research needs,
as well as standard language for reporting methods. These meth-
ods and analyses, therefore, can then be easily replicated or vali-
dated by other researchers. This will result in a standardized
approach to medications and comparable data across studies
regardless of the content of the classiﬁcation.
Although the framework we describe addresses research appli-
cation, it can also support clinical questions – for example, ‘‘Which
patients have been pharmacologically treated for depression?’’ posed
by Saitwal and colleagues [1]. Those authors demonstrated that
existing ontologies (SNOMED CT and UMLS Metathesauraus) can
be used to classify granular medication codes into groups that
are useful for queries on chronic disease management, quality
measurement, population health, or research cohort identiﬁcation.
The separation of coding and classiﬁcation tasks affords ﬂexibility
in selecting the most appropriate knowledge structure to support
multiple analyses of data for different questions and audiences.
Although still immature, our proposed framework provides
multiple targets for future research. In research contexts, evalua-
tion of coding systems revolves around validity (Do the codes accu-
rately represent the ‘‘true’’ medication entity or property?) and
reliability (Can the codes be consistently reproduced across coders,
systems, and time?) at the data collection stage. Using this frame-
work, measures of validity and reliability should be applied both to
candidate coding systems for data collection and storage, and to
candidate classiﬁcation systems that support querying, analysis,
and reporting. Previous approaches to the evaluation of coding sys-
tems have included coverage, structural features, management
processes for new terms, ease of use, and formal relationships
(i.e., ‘‘maps’’) to other relevant knowledge systems. Methods for
using scientiﬁc experts to validate coding and coding systems vary,
and the ideal number and types of experts are not clear. Because
coding systems themselves often cannot be separated from the
tools that support them, future coding system validation studies
might include usability heuristics [47] as well as the ways in which
the tools enable valid and reliable coding. One systematic review of
the performance of automated coding applications in biomedical
informatics attempted to identify uniform evaluation criteria, or
ways to compare coding systems and tools, but found that widely
varying study methods made it almost impossible to compare sys-
tem performance [48]. The methodological features that varied
most were the statistical methods used to evaluate system perfor-
mance and the mechanisms used to create a reference standard
against which the automated systems were evaluated [48]. The
authors of the review identiﬁed three general methods of
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or more independent reviewers with adjudication of disagree-
ments to establish consensus in some manner—for example, by
majority vote or review/discussion to obtain agreement; (b) a
‘‘trained standard’’ using one expert reviewer to classify the major-
ity of the training set, verifying the validity of the reviewer’s
assignment and providing training to improve the reviewer’s per-
formance/consistency; and (c) ‘‘regular practice’’ using one human
reviewer reﬂecting the normal or usual coding practice.
To date, the metric for coding efﬁciency has been inter-rater
reliability, which can be facilitated using multiple coders for real
or training cases. However, this metric has not been reported for
assessing medication coding in research. Implementation of a cod-
ing system in different clinical or research sites presents the same
challenges as the use of multiple data collectors in a single site,
although there might also be organizational or regional variations
in addition to individual variations in coding practice. Future re-
search should compare agreement of coding across individuals in
relation to interviewer/coder features (e.g., education, age, amount
of training). For multi-site studies, it is possible that additional
site-level data (e.g., clinical population features, such as distribu-
tion of indicator diseases and medication use) should be compared
[49].
Workﬂows for data coding in clinical research have not been
published, to our knowledge, and identifying optimal workﬂows
for collecting and analyzing medication data is an important infor-
matics research activity. Proposed workﬂows should include steps
for determining which classiﬁcation should be used for an analysis,
how to identify a limited but complete set of relevant classes, and
how to represent the encoded and classiﬁed data in analysis data
sets that can be used by future analysts. This knowledge would
support automated and reproducible medication classiﬁcation in
research settings, and perhaps extend to clinical decision support
and documentation.
6. Conclusion
Data coordinating centers must be prepared to support a wide
variety of study designs, research questions, disease domains, pa-
tient populations, and data sources in clinical research. Clinical re-
search informatics frameworks and tools can support the use of
standards across these spectra. Various study designs and imple-
mentation models present challenges for identifying the optimal
standards for medication data. Our framework supports the sepa-
ration of coding and classiﬁcation tasks. Further, the framework
identiﬁes different points in the research process where standard
coding and classiﬁcations systems can be implemented. Varying
requirements for medication classiﬁcation derive from different re-
search questions related to hypothesis testing and hypothesis gen-
eration. A common reference terminology, such as NDF-RT, can
support a standardized and reproducible approach to classifying
medications across research settings. Publicly available tools allow
the use of NDF-RT for this purpose, but future work is needed to
better integrate medication classiﬁcation into data management
and analysis workﬂows, and to assess the utility, validity, repro-
ducibility, and scalability of different subsets of the classiﬁcation.
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